Calidi Biotherapeutics Inc (CLDI) 13F Holdings Overview (Q2 2026)

CLDI ranks #7976 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

CLDI is a disclosed holding of Jane Street (Jane Street Group), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

24 institutions disclose a position in CLDI, but none treat it as a major bet — even Geode Capital Management, LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

Citigroup Inc has added to its CLDI position for two straight quarters, increasing it by $780.0 to reach $781.0 today.

HighTower Advisors, LLC has trimmed its CLDI position for two straight quarters, cutting it by $83.5K while still holding $14.2K.

CLDI reported a net loss of $19.9M in its latest fiscal year.

• Not yet profitable — net loss of $19.9M in the latest fiscal year
• Net income improved year over year, from -$22.1M to -$19.9M
• Operating cash flow was negative, using $21.3M in cash
• Current ratio of 1.59x — enough short-term assets to cover short-term liabilities
• Liabilities run 5098.00x equity — a highly leveraged balance sheet worth noting